1. Home
  2. ATYR vs NCMI Comparison

ATYR vs NCMI Comparison

Compare ATYR & NCMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • NCMI
  • Stock Information
  • Founded
  • ATYR 2005
  • NCMI 2005
  • Country
  • ATYR United States
  • NCMI United States
  • Employees
  • ATYR N/A
  • NCMI N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • NCMI Advertising
  • Sector
  • ATYR Health Care
  • NCMI Consumer Discretionary
  • Exchange
  • ATYR Nasdaq
  • NCMI Nasdaq
  • Market Cap
  • ATYR 451.3M
  • NCMI 458.3M
  • IPO Year
  • ATYR 2015
  • NCMI 2007
  • Fundamental
  • Price
  • ATYR $4.78
  • NCMI $4.77
  • Analyst Decision
  • ATYR Strong Buy
  • NCMI Strong Buy
  • Analyst Count
  • ATYR 6
  • NCMI 5
  • Target Price
  • ATYR $20.20
  • NCMI $7.40
  • AVG Volume (30 Days)
  • ATYR 5.8M
  • NCMI 498.8K
  • Earning Date
  • ATYR 08-12-2025
  • NCMI 08-05-2025
  • Dividend Yield
  • ATYR N/A
  • NCMI 2.49%
  • EPS Growth
  • ATYR N/A
  • NCMI N/A
  • EPS
  • ATYR N/A
  • NCMI N/A
  • Revenue
  • ATYR N/A
  • NCMI $238,300,000.00
  • Revenue This Year
  • ATYR $551.06
  • NCMI $7.90
  • Revenue Next Year
  • ATYR $1,874.58
  • NCMI $13.36
  • P/E Ratio
  • ATYR N/A
  • NCMI N/A
  • Revenue Growth
  • ATYR N/A
  • NCMI 42.10
  • 52 Week Low
  • ATYR $1.67
  • NCMI $4.12
  • 52 Week High
  • ATYR $7.29
  • NCMI $7.60
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 43.43
  • NCMI 43.68
  • Support Level
  • ATYR $5.46
  • NCMI $4.57
  • Resistance Level
  • ATYR $7.29
  • NCMI $5.09
  • Average True Range (ATR)
  • ATYR 0.64
  • NCMI 0.13
  • MACD
  • ATYR -0.13
  • NCMI 0.01
  • Stochastic Oscillator
  • ATYR 0.80
  • NCMI 16.67

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

Share on Social Networks: